Physical Optics Corporation — Department of Defense SBIR Phase I: To address the U.S. CBD need for novel autoinjector technology that provides the warfighte

Description

To address the U.S. CBD need for novel autoinjector technology that provides the warfighter with a compact, field-ready, cost-effective platform for long-term storage of any given CBT antidote that does not present a significant logistical burden, Physical Optics Corporation (POC) proposes to develop a Microfluidic Pneumatic Autoinjector (MPA) platform. The MPA will provide an innovative universal drug delivery platform that can provide long-term storage for next-generation CBT antidotes that is compact, lightweight, and robust for field use and enables autoinjection of wet-dry formulations in addition to single-component and multi-component wet formulations. The key components of the MPA include a novel design of the autoinjector and safety guards. These innovations will allow military personnel to self- or buddy-autoinject antidotes in full chem/bio protection gear. In Phase I, POC will demonstrate the feasibility of the MPA concept by developing a prototype that will meet the CBD performance metrics. POC plans to finalize the overall device design and manufacture and demonstrate the prototypes of the drug delivery system in Phase II. Also, POC will demonstrate to the DoD how this device is consistent with FDA guidelines and could be approved for drug injection via the 510(k) route.